Association of elevated vitamin B12 with oncohematological diseases in a cohort of 79,524 patients from Latvia
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-4.13930Keywords:
elevated total B12, myeloid leukemia, oncohematological diseasesAbstract
Summary. Aim: Currently there are some large-scale studies of elevated total vitamin B12 in relation to diseases and their prognosis. Aim of this retrospective study was to determine association of increased B12 as an additional diagnostic marker of oncohematological diseases by a statistical analysis of clinical data of 79,524 patients. Materials and Methods: Overall Latvian population representative data on B12 testing in 79,524 patients were obtained from laboratory database. The following exclusion criteria were applied: fluctuating B12 results within a three-month period, elevated (> 100 U/L) alanine transaminase or aspartate transaminase, hepatitis (HAV, HBV, and HCV) infection, reduced glomerular filtration rate (< 45 mL/min/1.73 m2). As a control group, individuals with normal B12 level and any oncologic diagnosis (solid cancer or hematological malignancies) were selected. Results: After application of step-by-step exclusion filters, 1,373 patients were left with significantly increased level of plasma B12 (> 1,700 pg/mL). Odds ratios for oncohematological diseases in total and myeloid leukemia (including acute, chronic and unspecified) in patient group with elevated B12 were found to be 6.0 (95% CI 4.7–7.6; p < 0.0001) and 19.2 (95% CI 13.1–28.0; p <0.0001), respectively, as compared to the control group. Conclusion: Elevated total B12 could be considered as a potential marker for oncohematological disorders.
References
Bender DA. Nutritional Biochemistry of the Vitamins. Cambridge: Cambridge University Press, 2003. 488 p.
Gräsbeck R. Biochemistry and clinical chemistry of vitamin B12 transport and the related diseases. Clin Biochem 1984; 17: 99–107.
Ermens AAM, Vlasveld LT, Lindemans J. Significance of elevated cobalamin (vitamin B12) levels in blood. Clin Biochem 2003; 36: 585–90.
Arendt JFH, Sørensen HT, Horsfall LJ, et al. Elevated vitamin B12 levels and cancer risk in UK primary care: A thin database cohort study. Cancer Epidemiol Biomarkers Prev 2019; 28: 814–21.
Ryg J, Nybo M, Hallas J. Cancer incidence in persons with elevated cobalamin levels. Eur J Clin Invest 2013; 43: 557–61.
Arendt JF, Pedersen L, Nexo E, et al. Elevated plasma vitamin B12 levels as a marker for cancer: A population-based cohort study. J Natl Cancer Inst 2013; 105: 1799–805.
Andrès E, Serraj K, Zhu J, et al. The pathophysiology of elevated vitamin B12 in clinical practice. QJM 2013; 106: 505–15.
Chiche L, Jean R, Romain F, et al. Clinical implications of high cobalamin blood levels for internal medicine. Rev Med Interne 2008; 29: 187–94 (in French).
Arendt JF, Nexo E. Unexpected high plasma cobalamin: proposal for a diagnostic strategy. Clin Chem Lab Med 2013; 51: 489–96.
Jammal M, Deneuville T, Mario N, et al. Concentration plasmatique élevée de la vitamine B12: un indicateur des maladies hépatiques ou tumorales. Rev Med Interne 2013; 34: 337–41 (in French).
Sugihara T, Koda M, Okamoto T, et al. Falsely elevated serum vitamin B12 levels were associated with the severity and prognosis of chronic viral liver disease. Yonago Acta Med 2017; 60: 31–9.
Carmel R, Vasireddy H, Aurangzeb I, George K. High serum cobalamin levels in the clinical setting — clinical associations and holo-transcobalamin changes. Clin Lab Haematol 2001; 23: 365–71.
Altman DG. Practical Statistics for Medical Research. New York: Chapman and Hall/CRC, 1999. 624 p.
Sheskin DJ. Handbook of Parametric and Nonparametric Statistical Procedures. New York: Chapman and Hall/CRC, 2000, 972 p.
Arendt JF, Nexo E. Cobalamin related parameters and disease patterns in patients with increased serum cobalamin levels. PLoS One 2012; 7:e45979.
Lin CY1, Kuo CS, Lu CL, et al. Elevated serum vitamin B(12) levels in association with tumor markers as the prognostic factors predictive for poor survival in patients with hepatocellular carcinoma. Nutr Cancer 2010; 62: 190–7.
Nexo E, Hoffmann-Lücke E. Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility. Am J Clin Nutr 2011; 94: 359S–65S.
Bowen RA, Dowdell KC, Dale JK, et al. Elevated vitamin B12 levels in autoimmune lymphoproliferative syndrome attributable to elevated haptocorrin in lymphocytes. Clin Biochem 2012; 45: 490–2.
Simonsen K, Rode A, Nicoll A, et al. Vitamin B12 and its binding proteins in hepatocellular carcinoma and chronic liver diseases. Scand J Gastroenterol 2014; 49: 1096–102.
Beard MF, Pitney WR, Sanneman EH. Serum Concentrations of Vitamin B12 in Patients Suffering from Leukemia. Blood 1954; 9: 789–94.
Rachmilewitz B, Rachmilewitz M, Moshkowitz B, et al. Serum transcobalamin in myeloid leukemia. J Lab Clin Med 1971; 78: 275–88.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
